Franklin FTSE United Kingdom ETF (ARCA: FLGB)

Ultime notizie per Franklin FTSE United Kingdom ETF (ARCA:FLGB)

Franklin FTSE United Kingdom ETF

Financial Services

Consumer Defensive

Industrials

Healthcare

Energy

Communication Services

Consumer Cyclical

Basic Materials

Utilities

Real Estate

Technology

Other

Under normal market conditions, the Fund invests at least 80 percent of its assets in the component securities of the FTSE UK Capped Index and in depositary receipts representing such securities. The FTSE UK Capped Index is a free float-adjusted market capitalization weighted index maintained and calculated by FTSE Russell with a capping methodology applied quarterly to issuer weights so that no single issuer of a component exceeds 25 percent of the FTSE UK Capped Index weight, and all issuers with weights above 5 percent do not cumulatively exceed 50 percent of the FTSE UK Capped Indexs weight. The FTSE UK Capped Index is based on the FTSE UK Index and is designed to measure the performance of United Kingdom large- and mid-capitalization stocks. FTSE Russell determines eligible securities for the FTSE UK Capped Index based on measures such as the companys place of incorporation, listing country, investor protection regulations present in the country of incorporation, tax domicile, location of headquarters/factors of production and currency of denomination.

Hsbc Holdings Plc,

Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) with a Buy and raises the price target from $40 to $42.

News

Price Target

Analyst Ratings

RPRX

Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $42

Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne <a href="https://www.benzinga.com/general/biotech">muscular dystrophy, effective July 22</a>. 
This reversal follows Sarepta's initial refusal to halt distribution despite a Food and Drug Administration (FDA) request amid safety concerns linked to patient deaths. 
The pause allows Sarepta and the FDA to complete a safety labeling update, including a black box warning for acute liver injury, and to <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46530056/sarepta-faces-regulatory-showdown-as-analysts-cut-price-targets">respond to FDA inquiries</a>. 
CEO Doug Ingram emphasized the decision was difficult but necessary to maintain a positive, collaborative relationship with regulators while prioritizing patient safety. The FDA previously placed clinical holds on Sarepta's related gene therapy trials after three deaths potentially associated with their products.
<a target="_blank" href="https://www.benzinga.com/quote/SRPT/analyst-ratings" rel="noreferrer noopener">William Blair writes</a>, &#8220;While we view the temporary pause of Elevidys shipments as unfortunate, especially for patients that were depending on receiving it in the near term, we believe the decision is necessary to rebuild the company&#8217;s relationship with the regulators and the patient community.
The FDA&#8217;s initial request also likely put heightened pressure on physicians to pause treatments.
Analyst Sami Corwin said the odds of Elevidys being formally withdrawn from the market &#8220;are very low.&#8221;
It&#8217;s uncertain how long the pause will last. However, William Blair expects Elevidys shipments to restart in the fourth quarter once the label update is complete. The analysts adjusted the forecast to include this delay. The firm estimates Elevidys will bring in $795.7 million in revenue for all of 2025.
For the second quarter, Sarepta expects: 
<ul class="wp-block-list">
<li>Net product revenue of $513 million</li>
<li>Elevidys revenue of $282 million, and </li>
<li>RNA-based PMOs net <a href="https://www.benzinga.com/news/fda/25/07/46473418/sarepta-therapeutics-reorganization-boosts-investor-confidence" target="_blank" rel="noreferrer noopener">product revenue of $231 million</a>.</li>
</ul>
Amid all the updates regarding Sarepta&#8217;s marketed or pipeline gene therapies, Arrowhead Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) stock closed 12.2% lower at $14.71.
For the unversed, in November 2024, Arrowhead announced a global licensing and collaboration <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/11/42196870/arrowhead-pharmaceuticals-shares-are-on-the-rise-today-whats-going-on" rel="noreferrer noopener">agreement with&nbsp;Sarepta Therapeutics</a>.
The partnership grants Sarepta exclusive worldwide rights to Arrowhead&#8217;s investigational RNA interference (RNAi) therapies for rare genetic diseases targeting muscle, the central nervous system (CNS), and the lungs.
The agreement focuses on Arrowhead&#8217;s Targeted RNAi Molecule platform, which enables precise delivery of therapies designed to reduce the activity of disease-causing genes.
Sarepta will pay Arrowhead $500 million and a $325 million equity investment at a 35% premium.
Additional terms include: 
<ul class="wp-block-list">
<li>$250 million to be paid in $50 million installments over five years</li>
<li>up to $300 million in near-term milestone payments over the next year, and </li>
<li>potential tiered royalties on commercial sales.</li>
</ul>
Price Action: SRPT stock is down 4.65% at $12.70 during the premarket session at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46539175/jpmorgan-chase-shakes-up-quantum-computing-division-recruits-state-streets-rob-otter-as-marco-pistoia-charles-lim-exit" target="_blank" rel="noreferrer noopener">JPMorgan Chase Shakes Up Quantum Computing Division, Recruits State Street&#8217;s Rob Otter As Marco Pistoia, Charles Lim Exit</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

Movers

Trading Ideas

General

ARWR

SRPT

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review

WIIM

SeaStar Medical Holding shares are trading higher after the company reported early safety results for QUELIMMUNE.

CNSP

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Citigroup analyst Geoff Meacham maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Neutral and raises the price target from $300 to $305.

AMGN

Citigroup Maintains Neutral on Amgen, Raises Price Target to $305

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $166 to $165.

JAZZ

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $165

<a href="https://events.q4inc.com/attendee/420437679" title="https://events.q4inc.com/attendee/420437679">https://events.q4inc.com/attendee/420437679</a>

Guidance

Coca-Cola CEO During Company's Q2 FY25 Conference Call Reportedly Says Volume Dipped In North America Due To Uncertainty And Puts Pressure On Socioeconomic Segments Of Consumers

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Benchmark raised Domino&#8217;s Pizza, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) price target from $535 to $540. Benchmark analyst Todd Brooks maintained a Buy rating. Domino&#8217;s shares closed at $462.24 on Monday. <a href="https://www.benzinga.com/quote/DPZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut the price target for PG&amp;E Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) from $22 to $20. Barclays analyst Nicholas Campanella maintained an Overweight rating. PG&amp;E shares closed at $13.38 on Monday. S<a href="https://www.benzinga.com/quote/PCG/analyst-ratings">ee how other analysts view this stock</a>.</li>
<li>Rosenblatt raised Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) price target from $56 to $65. Rosenblatt analyst Mike Genovese maintained a Buy rating. Calix shares closed at $53.73 on Monday. <a href="https://www.benzinga.com/quote/CALX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods boosted the price target for Veritex Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBTX#NASDAQ">VBTX</a>) from $30 to $37. Keefe, Bruyette &amp; Woods analyst Brady Gailey maintained a Market Perform rating. Veritex shares closed at $32.44 on Monday. <a href="https://www.benzinga.com/quote/VBTX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Cowen boosted the price target for Valero Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) from $118 to $140. TD Cowen analyst Jason Gabelman downgraded the stock from Buy to Hold. Valero Energy shares closed at $146.28 on Monday. <a href="https://www.benzinga.com/quote/VLO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank raised Etsy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) price target from $40 to $47. Deutsche Bank analyst Lee Horowitz maintained a Hold rating. Etsy shares settled at $60.41 on Monday. <a href="https://www.benzinga.com/quote/ETSY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein increased Domino&#8217;s Pizza, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) price target from $460 to $490. Bernstein analyst Danilo Gargiulo maintained a Market Perform rating. Domino&#8217;s shares closed at $462.24 on Monday. <a href="https://www.benzinga.com/quote/DPZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital raised Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) price target from $233 to $270. BMO Capital analyst Brian Pitz maintained an Outperform rating. Amazon shares closed at $229.30 on Monday.  <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham raised the price target for Penguin Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) from $27 to $30. Needham analyst Quinn Bolton maintained a Buy rating. Penguin Solutions shares settled at $24.58 on Monday. <a href="https://www.benzinga.com/quote/PENG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler increased ServiceTitan, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) price target from $125 to $150. Piper Sandler analyst Brent Bracelin reiterated an Overweight rating. ServiceTitan shares closed at $113.97 on Monday. <a href="https://www.benzinga.com/quote/TTAN/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AMZN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22085248/image-306-1024x578.png" alt="" class="wp-image-995387" style="width:604px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22085248/image-306-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22085248/image-306-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22085248/image-306-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22085248/image-306.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46517205/top-2-financial-stocks-that-may-plunge-this-month"> Top 2 Financial Stocks That May Plunge This Month</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

AMZN

CALX

ETSY

Penguin Solutions, Inc. - Ordinary Shares

PENG

TTAN

VBTX

Amazon To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday

KRMN

Karman Holdings shares are trading lower after the company announced an offering consisting of 20 million shares.

Wedbush analyst Daniel Ives reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and maintains $500 price target.

Reiteration

TSLA

Wedbush Reiterates Outperform on Tesla, Maintains $500 Price Target

General Motors Company slumped in Tuesday&#8217;s premarket session after reporting a sharp drop in adjusted EBIT margins to 6.4% and a <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">whopping $1.1 billion tariff headwind</a>.
The auto behemoth registered second-quarter adjusted earnings per share of $2.53, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46539248/gm-releases-2025-second-quarter-results" rel="noreferrer noopener">analyst consensus estimate of $2.40</a>. Quarterly sales of $47.12 billion outpaced the Street view of $45.57 billion.
Net sales in the Automotive segment totaled $42.869 billion, lower than $44.060 billion in the year-ago period.
Also Read: <a target="_blank" href="http://benzinga.com/markets/equities/25/07/46538669/us-stocks-likely-to-open-on-a-mixed-note-ahead-of-coca-cola-gm-lockheed-martin-earnings" rel="noreferrer noopener">US Stocks Likely To Open On A Mixed Note Ahead Of Coca-Cola, GM, Lockheed Martin Earnings</a>
In the U.S. market, the company&#8217;s market share rose to 17.4% for the second quarter of 2025, a 0.7 percentage point increase year-over-year. For the first half of 2025, U.S. market share stood at 17.3%, growing at a rate that outpaced the overall industry, according to the company press release.
&#8220;In the United States, we continue to lead the industry in full-size trucks and SUVs, and the 10 all-new or redesigned crossover SUVs we have introduced like the Chevrolet Trax, Buick Envista, and GMC Acadia took huge leaps forward in design and technology, resulting in record demand and revenue growth, while reduced complexity contributed to stronger profitability,&#8221; said CEO Mary Barra in the company&#8217;s <a target="_blank" href="https://investor.gm.com/news-releases/news-release-details/q2-2025-letter-shareholders" rel="noreferrer noopener">letter</a> to shareholders.
Adjusted EBIT margin contracted to 6.4% in the quarter under review from 9.3% in the year-ago period. Adjusted EBIT <a target="_blank" href="https://investor.gm.com/static-files/eaf4a73f-ef85-4134-8533-902e6a9a8177" rel="noreferrer noopener">decreased</a> to $3.037 billion from $4.438 billion primarily due to a net tariff impact of $1.1 billion, with minimal mitigation offsets. Net income margin contracted to 4% from 6.1%.
The firm expects the third quarter net tariff impact to exceed that of the second quarter, driven by the timing of indirect tariff costs. The heavier weighting of these costs in the third quarter will result in a higher overall net impact.
&#8220;In China, the performance of our new energy vehicles has been especially strong, and in the second quarter, we reported our second consecutive quarter of year-over-year sales growth,&#8221; Barra added. &#8220;We gained the most share among foreign OEMs, and we reported positive equity income.&#8221;
In June, the firm announced $4 billion of new investment in U.S. assembly plants to add 300,000 units of capacity for high-margin light-duty pickups, full-size SUVs, and crossovers.
The CEO highlighted that this development will &#8220;unmet customer demand, greatly reduce our tariff exposure, and capture upside opportunities as we launch new models.&#8221;
The capacity begins coming online in just 18 months, after which General Motors plans to build more than 2 million vehicles in the U.S. each year.
The company exited the quarter with cash and equivalents worth $22.381 billion, higher than $19.872 billion as of December 31, 2024.
<h2 class="wp-block-heading">Outlook</h2>
General Motors affirms FY25 adjusted earnings per share&nbsp;guidance&nbsp;of&nbsp;$8.25-$10.00&nbsp;versus&nbsp;$9.17&nbsp;analyst estimate.
General Motors is keeping its full‑year 2025 guidance unchanged while planning to offset at least 30% of the $4 billion–$5 billion gross tariff impact.
It will achieve this mitigation equally through manufacturing adjustments, targeted cost initiatives, and consistent pricing.
Price Action: GM shares are trading lower by 2.43% to $51.77&nbsp;premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46513468/bitcoin-miner-iren-could-surge-1572-as-sotp-valuation-pegs-300-target-hedge-fund-manager-eric-jackson-says-were-cooking-with-gas" target="_blank" rel="noreferrer noopener">Bitcoin Miner IREN Could Surge 1,572% As SOTP Valuation Pegs $300 Target — Hedge Fund Manager Eric Jackson Says, &#8216;We&#8217;re Cooking With Gas&#8217;</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Earnings

Equities

General Motors Faces Tariffs Heat, Margins Shrink

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight and raises the price target from $148 to $150.

NBIX

Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $150

Badget Meter shares are trading lower after the company announced a Q2 EPS miss.

Keybanc analyst Brett Fishbin maintains Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight and raises the price target from $277 to $288.

Keybanc Maintains Overweight on Steris, Raises Price Target to $288

REBN

Reborn Coffee shares are trading higher after the company announced it has expanded into Georgia and Armenia through its licensing agreement with Arjomand Group and IG International.

Oriental Rise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIS#NASDAQ">ORIS</a>) (&quot;Oriental Rise&quot; or the &quot;Company&quot;), an integrated supplier of white- and black-tea products in mainland China, today announced the pricing of its public offering (the &quot;Offering&quot;) of up to 14,800,000 Units on a best-efforts basis at a price of US$0.4681 per Unit. Each Unit consists of one Ordinary Share (or one Pre-Funded Warrant to purchase one Ordinary Share in lieu thereof), par value US$0.0008 per share, and one Common Warrant to purchase one Ordinary Share. Each Common Warrant is exercisable immediately on the date of issuance at an exercise price of US$0.4681 per share and will expire five years from the date of issuance. The Common Warrants may, at any time following the closing of this Offering and in the holders&#39; sole discretion, be exercised in whole or in part by means of a zero exercise price option, in which the holders will receive two (2) times the number of Ordinary Shares that would be issuable upon a cash exercise of the Common Warrant, without payment of additional consideration. In addition, the exercise price for the Common Warrants will be adjusted downward on the 5th and 10th trading days following the closing of this Offering to the price that is equal to 70% and 50%, respectively, of the initial exercise price of the Common Warrants; and upon each adjustment to the exercise price for the Common Warrants, the number of issuable warrant shares will be proportionately increased so that the nominal aggregate exercise price of the Common Warrants will remain the same. Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately US$6.9 million.
The Offering is expected to close on July 23, 2025, subject to customary closing conditions. The Company intends to use the proceeds from the Offering for general corporate purposes and working capital, sales network expansion, including the hiring of sale personnel and the development of regional sales channels, and expansion of production and capacity, including new equipment and upgrades to its manufacturing facilities.
Maxim Group LLC is acting as the exclusive placement agent, on a reasonable best-efforts basis for the Offering.

Offerings

ORIS

Oriental Rise Prices $6.9M Public Offering Of 14.8M Units At $0.4681 Per Unit; Including Ordinary Shares And Warrants With Adjustable Exercise Prices

Could a fresh coat of paint be losing its luster in the financial world? As Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) faces a surprising dip in its stock despite surpassing revenue expectations, the real story might be hidden in the fine print <a href="https://www.benzinga.com/pressreleases/25/07/n46539895/the-sherwin-williams-company-reports-2025-second-quarter-financial-results">of its earnings report.</a>
Sherwin-Williams stock declined on Tuesday after it reported its second-quarter results. The American paints and coatings company reported quarterly adjusted earnings per share of $3.38, below the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">Wall Street view</a> of $3.81. 
Quarterly revenue of $6.31 billion&nbsp;beat the analyst consensus of $6.30 billion.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45390940/sherwin-williams-shw-stock-gains-on-recent-q1-earnings-beat-dividend-hike" rel="noreferrer noopener">Sherwin-Williams (SHW) Stock Gains On Recent Q1 Earnings Beat, Dividend Hike</a>
Consolidated net sales increased 0.7% in the quarter.
Net sales from stores in the Paint Stores Group that have been open for more than 12 calendar months increased 0.8% in the quarter.
Quarterly gross profit increased to $3.12 billion from $3.06 billion a year ago. Gross margin in the quarter under review expanded to 49.4% from 48.8% a year ago.
The company returned $0.72 billion in cash to shareholders as dividends and repurchased shares of its common stock during the quarter. 
Sherwin-Williams exited the quarter with cash and equivalents worth $269.8 million.
Chair and CEO Heidi G. Petz noted Sherwin-Williams executed its disciplined strategy amid a choppy demand environment, delivering gross margin expansion for the 12th straight quarter and keeping consolidated sales within its guidance range. In response to persistent demand softness—which the company expects to continue or worsen in the second half—it accelerated and expanded restructuring efforts, incurring $59 million in pre-tax charges. Progress on its new buildings project also moved faster than expected, leading to $40 million in transition-related costs initially anticipated for the second half.
The Paint Stores Group saw continued strength in protective and marine sales, which rose by high-single digits for the fourth straight quarter. Residential repaint also posted mid-single-digit gains in a weak market. Meanwhile, commercial, new residential, and property maintenance segments remained under pressure. Consumer Brands Group sales declined due to soft North American DIY demand and unfavorable currency impacts in Latin America, though Europe provided some offset. Performance Coatings Group grew in Europe, Asia, and Latin America, but North American sales lagged. Packaging led the group with double-digit sales growth.
Given weaker-than-expected demand through June and no signs of near-term improvement, Sherwin-Williams revised its full-year guidance downward. The company doubled its restructuring efforts to adapt to a prolonged slowdown but remains committed to its long-term growth strategy. Confident it&#8217;s nearing a competitive inflection point, Sherwin-Williams continues investing in customer relationships and market share gains to drive future shareholder returns.
Outlook:&nbsp;Sherwin-Williams expects third-quarter revenue to be up or down a low-single-digit percentage compared to the third quarter of 2024.
The company lowered its 2025 adjusted EPS guidance to $11.20-$11.50 (<a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/45080514/sherwin-williams-reports-mixed-q1-results-in-choppy-demand-environment" rel="noreferrer noopener">prior $11.65-$12.05</a>), compared to the $11.88 <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst consensus estimate</a>.
It expects consolidated net sales to be up or down by a low single-digit percentage compared to full-year 2024 (prior low single-digit percentage range).
Sherwin-Williams lowered 2025 GAAP EPS guidance to $10.11-$10.41 (prior $10.70-$11.10) versus $11.09 analyst consensus estimate.
SHW Price Action: Sherwin-Williams shares were down 3.62% at $328.95 during premarket trading on Tuesday, <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46538668/apples-online-store-is-now-live-in-saudi-arabia-flagship-stores-coming-by-2026" target="_blank" rel="noreferrer noopener">Apple&#8217;s Online Store Is Now Live In Saudi Arabia, Flagship Stores Coming By 2026</a></li>
</ul>
Photo: JHVEPhoto/Shutterstock

Sherwin-Williams Falls As Q2 Profit Disappoints, Forecasts Trimmed With No Quick Demand Rebound In Sight

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and lowers the price target from $97 to $96.

BMRN

Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $96

Citigroup analyst Judy Zhang upgrades UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) from Neutral to Buy and raises the price target from $9.5 to $14.

Upgrades

TIGR

Citigroup Upgrades UP Fintech Holding to Buy, Raises Price Target to $14

Pop Culture Group Co., Ltd ("CPOP" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPOP#NASDAQ">CPOP</a>)&nbsp;today announced that it has officially signed an exclusive collaboration with renowned trend comics artist Li Guo. With his avant-garde comic style, Li Guo will fuse the Company's classic aesthetics with contemporary youth culture to co-create a new IP series, further expanding the company's strategic layout in the field of trendy culture.

CPOP

Pop Culture Group Officially Signs Exclusive Collaboration With Renowned Trend Comics Artist Li Guo

Comments

Franklin FTSE United Kingdom ETF

Notizie

Ultime notizie per Franklin FTSE United Kingdom ETF (ARCA:FLGB)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO